Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Study Comparing the Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistent Asthma
A Randomized, Double-Blind, Parallel Group, Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistent Asthma
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| GP MDI 28.8 μg | Experimental | GP MDI 14.4 μg per actuation taken as 2 inhalations BID |
|
| GP MDI 14.4 μg | Experimental | GP MDI 7.2 μg per actuation taken as 2 inhalations BID |
|
| GP MDI 7.2 μg | Experimental | GP MDI 3.6 μg per actuation taken as 2 inhalations BID |
|
| Placebo MDI | Placebo Comparator | Taken as 2 inhalations BID |
|
| Spiriva Respimat 2.5 μg | Other | Open Label Spiriva Respimat 2.5 μg |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| GP MDI 28.8 μg | Drug | GP MDI (PT001)14.4 μg per actuation taken as 2 inhalations BID |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4) | Change from baseline in forced expiratory volume in 1 second (FEV1) area under the curve from 0 to 4 hours (AUC0-4)AUC was normalized for length of follow up (e.g. typically 4 hours). | Week 24 |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Morning Pre-dose Trough FEV1 | Week 24 | |
| Rate of Moderate to Severe Asthma Exacerbations | Rate of moderate to severe Asthma exacerbations (A deterioration of asthma requiring a new or increased dose of ICS for at least 3 days) or severe Asthma exacerbation (Use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days OR a hospitalization or ER visit because of asthma) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Birmingham | Alabama | 35209 | United States | ||
| Research Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36472162 | Derived | Oba Y, Anwer S, Maduke T, Patel T, Dias S. Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying doses of inhaled corticosteroids in adolescents and adults with asthma: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2022 Dec 6;12(12):CD013799. doi: 10.1002/14651858.CD013799.pub2. |
| Label | URL |
|---|---|
| Related Info | View source |
Not provided
Subjects were randomized in a 2:2:2:2:1 Scheme to follow 1 of the 5 treatment groups.
The study randomized subjects at 194 sites in the United States from December 2017 to September 2019. The entire study period was scheduled to take up to approximately 26 weeks for each individual subject from the time of screening through the follow up period.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | GP MDI 28.8 μg | Glycopyrronium Metered Dose Inhalation 28.8 μg |
| FG001 | GP MDI 14.4 μg | Glycopyrronium Metered Dose Inhalation 14.4 μg |
| Title | Milestones | Reasons Not Completed | ||||
|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Mar 8, 2019 | May 22, 2020 |
Not provided
Not provided
Linear repeated measures model
Not provided
Not provided
Double Blind vs Placebo, Open Label Spiriva Respimat
| GP MDI 14.4 μg | Drug | GP MDI (PT001) 7.2 μg per actuation taken as 2 inhalations BID |
|
|
| GP MDI 7.2 μg | Drug | GP MDI (PT001) 3.6 μg per actuation taken as 2 inhalations BID |
|
|
| Placebo MDI | Drug | Placebo taken as 2 inhalations BID |
|
|
| Spiriva Respimat 2.5 μg | Drug | Spiriva Respimat 2.5 μg QD (open-label) |
|
|
| over 24 Weeks (timepoints of 4, 12 & 20 weeks) |
| Change From Baseline in ACQ-7 (Asthma Control Questionnaire) | ACQ-7: The ACQ, comprising 7 questions, is completed in the clinic and requires subjects to recall their experiences during the previous week (7 days) prior to the study visit. The ACQ-5 measures 5 symptoms (woken at night by symptoms, wake in the morning with symptoms, limitation of daily activities, shortness of breath, and wheeze); the ACQ-6 is these symptom measurements plus daily rescue medication use as recalled by the subject; and the ACQ 7 is the ACQ 6 plus airway caliber as measured by pre-bronchodilator FEV1 percent predicted. Each question is scored on a 7-point scale (generally, 0=no impairment, 6=maximum impairment), the questions are equally weighted, and the ACQ score is the mean of the item responses and therefore ranges from 0 (totally controlled) to 6 (severely uncontrolled. | Week 24 |
| Change From Baseline in ACQ-5 (Asthma Control Questionnaire) | ACQ-5:The ACQ-5 measures 5 symptoms (woken at night by symptoms, wake in the morning with symptoms, limitation of daily activities, shortness of breath, and wheeze). Each question is scored on a 7-point scale (generally, 0=no impairment, 6=maximum impairment), the questions are equally weighted, and the ACQ score is the mean of the item responses and therefore ranges from 0 (totally controlled) to 6 (severely uncontrolled). | Week 24 |
| Change From Baseline in Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ +12) | AQLQ +12 - Asthma Quality of Life Questionnaire The AQLQ +12 is a 32-item validated subject-administered questionnaire that was developed to measure the functional problems (physical, emotional, social and occupational) that are most troublesome to adults (≥18 years of age) and adolescents (12 to 17 years of age) with asthma. The 32 questions in the AQLQ +12 are in 4 domains (symptoms, activity limitation, emotional function, and environmental stimuli). All 4 domains contain standard specific questions relating to each domain. Subjects are asked to think about how they have been during the previous 2 weeks. Responses to each of the 32 questions are on a 7-point scale (7=no impairment to 1=severe impairment). The overall AQLQ +12 score is the mean of all 32 responses. Overall scores range from 1=severe impairment to 7=no impairment. | Week 24 |
| Birmingham |
| Alabama |
| 35243 |
| United States |
| Research Site | Dothan | Alabama | 36303 | United States |
| Research Site | Guntersville | Alabama | 35976 | United States |
| Research Site | Jasper | Alabama | 35501 | United States |
| Research Site | Scottsboro | Alabama | 35768 | United States |
| Research Site | Chandler | Arizona | 85224 | United States |
| Research Site | Flagstaff | Arizona | 86001 | United States |
| Research Site | Phoenix | Arizona | 85018 | United States |
| Research Site | Tempe | Arizona | 85283 | United States |
| Research Site | Tucson | Arizona | 85710 | United States |
| Research Site | Tucson | Arizona | 85745 | United States |
| Research Site | Little Rock | Arkansas | 72205 | United States |
| Research Site | Little Rock | Arkansas | 72209 | United States |
| Research Site | Little Rock | Arkansas | 72212 | United States |
| Research Site | Anaheim | California | 92801 | United States |
| Research Site | Bakersfield | California | 93301 | United States |
| Research Site | Corona | California | 92879 | United States |
| Research Site | Costa Mesa | California | 92627 | United States |
| Research Site | El Cajon | California | 92020 | United States |
| Research Site | Encinitas | California | 92024 | United States |
| Research Site | Fresno | California | 93702 | United States |
| Research Site | Fullerton | California | 92835 | United States |
| Research Site | Gold River | California | 95670 | United States |
| Research Site | Huntington Beach | California | 92647 | United States |
| Research Site | Long Beach | California | 90036 | United States |
| Research Site | Long Beach | California | 90806 | United States |
| Research Site | Los Angeles | California | 90017 | United States |
| Research Site | Los Angeles | California | 90048 | United States |
| Research Site | Mission Viejo | California | 92691 | United States |
| Research Site | Newport Beach | California | 92663 | United States |
| Research Site | North Hollywood | California | 91606 | United States |
| Research Site | Northridge | California | 91324 | United States |
| Research Site | Orange | California | 92868 | United States |
| Research Site | Palmdale | California | 93551 | United States |
| Research Site | Poway | California | 92064 | United States |
| Research Site | Quartz Hill | California | 93536 | United States |
| Research Site | Rancho Mirage | California | 92270 | United States |
| Research Site | Riverside | California | 92506 | United States |
| Research Site | Rolling Hills Estates | California | 90274 | United States |
| Research Site | Sacramento | California | 95821 | United States |
| Research Site | Sacramento | California | 95823 | United States |
| Research Site | Sacramento | California | 95831 | United States |
| Research Site | San Diego | California | 92117 | United States |
| Research Site | San Diego | California | 92119 | United States |
| Research Site | San Diego | California | 92120 | United States |
| Research Site | San Diego | California | 92123 | United States |
| Research Site | San Jose | California | 95117 | United States |
| Research Site | Stockton | California | 95207 | United States |
| Research Site | Thousand Oaks | California | 91360 | United States |
| Research Site | Tustin | California | 92780 | United States |
| Research Site | Westminster | California | 92683 | United States |
| Research Site | Centennial | Colorado | 80112 | United States |
| Research Site | Colorado Springs | Colorado | 80907 | United States |
| Research Site | Colorado Springs | Colorado | 80910 | United States |
| Research Site | Lafayette | Colorado | 80026 | United States |
| Research Site | Wheat Ridge | Colorado | 80033 | United States |
| Research Site | Hamden | Connecticut | 06517 | United States |
| Research Site | Aventura | Florida | 33180 | United States |
| Research Site | Brandon | Florida | 33511 | United States |
| Research Site | Clearwater | Florida | 33756 | United States |
| Research Site | Clearwater | Florida | 33765 | United States |
| Research Site | Gainesville | Florida | 32653 | United States |
| Research Site | Hialeah | Florida | 33012 | United States |
| Research Site | Hialeah | Florida | 33013 | United States |
| Research Site | Hialeah | Florida | 33016 | United States |
| Research Site | Kissimmee | Florida | 34741 | United States |
| Research Site | Lake City | Florida | 32055 | United States |
| Research Site | Loxahatchee Groves | Florida | 33470 | United States |
| Research Site | Miami | Florida | 33126 | United States |
| Research Site | Miami | Florida | 33174 | United States |
| Research Site | Miami | Florida | 33175 | United States |
| Research Site | Miami | Florida | 33176 | United States |
| Research Site | Miami | Florida | 33186 | United States |
| Research Site | Ocala | Florida | 34471 | United States |
| Research Site | Ocoee | Florida | 34761 | United States |
| Research Site | Orlando | Florida | 32811 | United States |
| Research Site | Panama City | Florida | 32405 | United States |
| Research Site | Pembroke Pines | Florida | 33029 | United States |
| Research Site | Saint Cloud | Florida | 34769 | United States |
| Research Site | Tallahassee | Florida | 32308 | United States |
| Research Site | Tampa | Florida | 33603 | United States |
| Research Site | Winter Park | Florida | 32789 | United States |
| Research Site | Adairsville | Georgia | 30103 | United States |
| Research Site | Albany | Georgia | 31707 | United States |
| Research Site | Atlanta | Georgia | 30345 | United States |
| Research Site | Columbus | Georgia | 31904 | United States |
| Research Site | Dacula | Georgia | 30019 | United States |
| Research Site | Gainesville | Georgia | 30501 | United States |
| Research Site | Lawrenceville | Georgia | 30046 | United States |
| Research Site | Norcross | Georgia | 30071 | United States |
| Research Site | Rincon | Georgia | 31326 | United States |
| Research Site | Savannah | Georgia | 31406 | United States |
| Research Site | Stockbridge | Georgia | 30281 | United States |
| Research Site | Boise | Idaho | 83706 | United States |
| Research Site | Meridian | Idaho | 83646 | United States |
| Research Site | Evergreen Park | Illinois | 60805 | United States |
| Research Site | O'Fallon | Illinois | 62269 | United States |
| Research Site | River Forest | Illinois | 60305 | United States |
| Research Site | Brownsburg | Indiana | 46112 | United States |
| Research Site | Michigan City | Indiana | 46360 | United States |
| Research Site | Fort Mitchell | Kentucky | 41017 | United States |
| Research Site | Crowley | Louisiana | 70526 | United States |
| Research Site | Shreveport | Louisiana | 71106 | United States |
| Research Site | Zachary | Louisiana | 70791 | United States |
| Research Site | Bangor | Maine | 04401 | United States |
| Research Site | Chevy Chase | Maryland | 20815 | United States |
| Research Site | White Marsh | Maryland | 21162 | United States |
| Research Site | Fall River | Massachusetts | 02721 | United States |
| Research Site | North Dartmouth | Massachusetts | 02747 | United States |
| Research Site | Ann Arbor | Michigan | 48106 | United States |
| Research Site | Farmington Hills | Michigan | 48336 | United States |
| Research Site | Rochester | Michigan | 48307 | United States |
| Research Site | Troy | Michigan | 48085 | United States |
| Research Site | Edina | Minnesota | 55435 | United States |
| Research Site | Fridley | Minnesota | 55432 | United States |
| Research Site | Minneapolis | Minnesota | 55402 | United States |
| Research Site | Minneapolis | Minnesota | 55407 | United States |
| Research Site | Woodbury | Minnesota | 55125 | United States |
| Research Site | Chesterfield | Missouri | 63017 | United States |
| Research Site | Columbia | Missouri | 65203 | United States |
| Research Site | Saint Charles | Missouri | 63301 | United States |
| Research Site | St Louis | Missouri | 63141 | United States |
| Research Site | Bellevue | Nebraska | 68005 | United States |
| Research Site | Bellevue | Nebraska | 68123 | United States |
| Research Site | Lincoln | Nebraska | 68505 | United States |
| Research Site | Omaha | Nebraska | 68114 | United States |
| Research Site | Las Vegas | Nevada | 89106 | United States |
| Research Site | Las Vegas | Nevada | 89119 | United States |
| Research Site | Las Vegas | Nevada | 89146 | United States |
| Research Site | Reno | Nevada | 89503 | United States |
| Research Site | Berlin | New Jersey | 08009 | United States |
| Research Site | Ocean City | New Jersey | 07712 | United States |
| Research Site | Skillman | New Jersey | 08558 | United States |
| Research Site | Toms River | New Jersey | 08755 | United States |
| Research Site | Albuquerque | New Mexico | 87108 | United States |
| Research Site | Albuquerque | New Mexico | 87109 | United States |
| Research Site | Cortland | New York | 13045 | United States |
| Research Site | New York | New York | 10016 | United States |
| Research Site | The Bronx | New York | 10455 | United States |
| Research Site | The Bronx | New York | 10468 | United States |
| Research Site | Watertown | New York | 13601 | United States |
| Research Site | Burlington | North Carolina | 27215 | United States |
| Research Site | Charlotte | North Carolina | 28207 | United States |
| Research Site | Charlotte | North Carolina | 28277 | United States |
| Research Site | Elizabeth City | North Carolina | 27909 | United States |
| Research Site | Gastonia | North Carolina | 28054 | United States |
| Research Site | Greensboro | North Carolina | 27408 | United States |
| Research Site | Hickory | North Carolina | 28078 | United States |
| Research Site | Huntersville | North Carolina | 28078 | United States |
| Research Site | Monroe | North Carolina | 28112 | United States |
| Research Site | Mooresville | North Carolina | 28117 | United States |
| Research Site | New Bern | North Carolina | 28562 | United States |
| Research Site | Raleigh | North Carolina | 27612 | United States |
| Research Site | Winston-Salem | North Carolina | 27103 | United States |
| Research Site | Fargo | North Dakota | 58103 | United States |
| Research Site | Fargo | North Dakota | 58104 | United States |
| Research Site | Cincinnati | Ohio | 45219 | United States |
| Research Site | Cincinnati | Ohio | 45231 | United States |
| Research Site | Cincinnati | Ohio | 45242 | United States |
| Research Site | Columbus | Ohio | 43207 | United States |
| Research Site | Dayton | Ohio | 45419 | United States |
| Research Site | Dayton | Ohio | 45459 | United States |
| Research Site | Dublin | Ohio | 43016 | United States |
| Research Site | Marion | Ohio | 43302 | United States |
| Research Site | Wooster | Ohio | 44691 | United States |
| Research Site | Edmond | Oklahoma | 73034 | United States |
| Research Site | Oklahoma City | Oklahoma | 73131 | United States |
| Research Site | Tulsa | Oklahoma | 74136 | United States |
| Research Site | Clackamas | Oregon | 97015-5737 | United States |
| Research Site | Medford | Oregon | 97504 | United States |
| Research Site | Portland | Oregon | 97202 | United States |
| Research Site | Monroeville | Pennsylvania | 15665 | United States |
| Research Site | Pittsburgh | Pennsylvania | 15236 | United States |
| Research Site | Pittsburgh | Pennsylvania | 15241 | United States |
| Research Site | Wyomissing | Pennsylvania | 19610 | United States |
| Research Site | East Providence | Rhode Island | 02914 | United States |
| Research Site | Warwick | Rhode Island | 02886 | United States |
| Research Site | Anderson | South Carolina | 29621 | United States |
| Research Site | Charleston | South Carolina | 29406 | United States |
| Research Site | Gaffney | South Carolina | 29340 | United States |
| Research Site | Gaffney | South Carolina | 29341 | United States |
| Research Site | Greenville | South Carolina | 29615 | United States |
| Research Site | Hodges | South Carolina | 29653 | United States |
| Research Site | Mt. Pleasant | South Carolina | 29464 | United States |
| Research Site | Myrtle Beach | South Carolina | 29588 | United States |
| Research Site | Rock Hill | South Carolina | 29732 | United States |
| Research Site | Spartanburg | South Carolina | 29301 | United States |
| Research Site | Spartanburg | South Carolina | 29303 | United States |
| Research Site | Union | South Carolina | 29379 | United States |
| Research Site | Rapid City | South Dakota | 57702 | United States |
| Research Site | Franklin | Tennessee | 37067 | United States |
| Research Site | Hendersonville | Tennessee | 37075 | United States |
| Research Site | Johnson City | Tennessee | 37601 | United States |
| Research Site | Smyrna | Tennessee | 37167 | United States |
| Research Site | Amarillo | Texas | 79106 | United States |
| Research Site | Austin | Texas | 78759 | United States |
| Research Site | Boerne | Texas | 78006 | United States |
| Research Site | Carrollton | Texas | 75007 | United States |
| Research Site | Dallas | Texas | 75231 | United States |
| Research Site | Dallas | Texas | 75235 | United States |
| Research Site | El Paso | Texas | 79903 | United States |
| Research Site | Houston | Texas | 77058 | United States |
| Research Site | Houston | Texas | 77074 | United States |
| Research Site | Houston | Texas | 77099 | United States |
| Research Site | Kerrville | Texas | 78028 | United States |
| Research Site | Killeen | Texas | 76542 | United States |
| Research Site | Lampasas | Texas | 76550 | United States |
| Research Site | Live Oak | Texas | 78233 | United States |
| Research Site | Lufkin | Texas | 75904 | United States |
| Research Site | Pearland | Texas | 77584 | United States |
| Research Site | Plano | Texas | 75093 | United States |
| Research Site | San Antonio | Texas | 78205 | United States |
| Research Site | San Antonio | Texas | 78215 | United States |
| Research Site | San Antonio | Texas | 78229 | United States |
| Research Site | San Antonio | Texas | 78258 | United States |
| Research Site | Sherman | Texas | 75092 | United States |
| Research Site | Tomball | Texas | 77375 | United States |
| Research Site | Waco | Texas | 76712 | United States |
| Research Site | Murray | Utah | 84107 | United States |
| Research Site | Salt Lake City | Utah | 84102 | United States |
| Research Site | Salt Lake City | Utah | 84107 | United States |
| Research Site | South Burlington | Vermont | 05403 | United States |
| Research Site | Abingdon | Virginia | 24210 | United States |
| Research Site | Newport News | Virginia | 23606 | United States |
| Research Site | Richmond | Virginia | 23114 | United States |
| Research Site | Richmond | Virginia | 23226 | United States |
| Research Site | Bellingham | Washington | 98225 | United States |
| Research Site | Spokane Valley | Washington | 99216 | United States |
| Research Site | Tacoma | Washington | 98405 | United States |
| Research Site | Morgantown | West Virginia | 26505 | United States |
| Research Site | Greenfield | Wisconsin | 53228 | United States |
| Related Info | View source |
| FG002 | GP MDI 7.2 μg | Glycopyrronium Metered Dose Inhalation 7.2μg |
| FG003 | Placebo MDI | Placebo Metered Dose Inhalation |
| FG004 | Spiriva Respimat 2.5 μg | Spiriva Respimat 2.5 μg |
|
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | GP MDI 28.8 μg | Glycopyrronium Metered Dose Inhalation 28.8 μg |
| BG001 | GP MDI 14.4 μg | Glycopyrronium Metered Dose Inhalation 14.4 μg |
| BG002 | GP MDI 7.2 μg | Glycopyrronium Metered Dose Inhalation 7.2μg |
| BG003 | Placebo MDI | Placebo Metered Dose Inhalation |
| BG004 | Spiriva Respimat 2.5 μg | Spiriva Respimat 2.5 μg |
| BG005 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Safety Population | Mean | Standard Deviation | Years |
| ||||||||||||||
| Sex: Female, Male | Safety Population | Count of Participants | Participants |
| |||||||||||||||
| Ethnicity (NIH/OMB) | Safety Population | Count of Participants | Participants |
| |||||||||||||||
| Race (NIH/OMB) | Safety Population | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4) | Change from baseline in forced expiratory volume in 1 second (FEV1) area under the curve from 0 to 4 hours (AUC0-4)AUC was normalized for length of follow up (e.g. typically 4 hours). | mITT Population | Posted | Least Squares Mean | 95% Confidence Interval | Liter | Week 24 |
|
|
| |||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Morning Pre-dose Trough FEV1 | mITT Population | Posted | Least Squares Mean | 95% Confidence Interval | Liter | Week 24 |
|
| |||||||||||||||||||||||||||||||||||||||
| Secondary | Rate of Moderate to Severe Asthma Exacerbations | Rate of moderate to severe Asthma exacerbations (A deterioration of asthma requiring a new or increased dose of ICS for at least 3 days) or severe Asthma exacerbation (Use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days OR a hospitalization or ER visit because of asthma) | mITT Population | Posted | Mean | Standard Error | Events per year | over 24 Weeks (timepoints of 4, 12 & 20 weeks) |
| |||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in ACQ-7 (Asthma Control Questionnaire) | ACQ-7: The ACQ, comprising 7 questions, is completed in the clinic and requires subjects to recall their experiences during the previous week (7 days) prior to the study visit. The ACQ-5 measures 5 symptoms (woken at night by symptoms, wake in the morning with symptoms, limitation of daily activities, shortness of breath, and wheeze); the ACQ-6 is these symptom measurements plus daily rescue medication use as recalled by the subject; and the ACQ 7 is the ACQ 6 plus airway caliber as measured by pre-bronchodilator FEV1 percent predicted. Each question is scored on a 7-point scale (generally, 0=no impairment, 6=maximum impairment), the questions are equally weighted, and the ACQ score is the mean of the item responses and therefore ranges from 0 (totally controlled) to 6 (severely uncontrolled. | mITT Population | Posted | Least Squares Mean | 95% Confidence Interval | Scores on a scale | Week 24 |
| |||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in ACQ-5 (Asthma Control Questionnaire) | ACQ-5:The ACQ-5 measures 5 symptoms (woken at night by symptoms, wake in the morning with symptoms, limitation of daily activities, shortness of breath, and wheeze). Each question is scored on a 7-point scale (generally, 0=no impairment, 6=maximum impairment), the questions are equally weighted, and the ACQ score is the mean of the item responses and therefore ranges from 0 (totally controlled) to 6 (severely uncontrolled). | mITT Population | Posted | Least Squares Mean | 95% Confidence Interval | Scores on a scale | Week 24 |
| |||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ +12) | AQLQ +12 - Asthma Quality of Life Questionnaire The AQLQ +12 is a 32-item validated subject-administered questionnaire that was developed to measure the functional problems (physical, emotional, social and occupational) that are most troublesome to adults (≥18 years of age) and adolescents (12 to 17 years of age) with asthma. The 32 questions in the AQLQ +12 are in 4 domains (symptoms, activity limitation, emotional function, and environmental stimuli). All 4 domains contain standard specific questions relating to each domain. Subjects are asked to think about how they have been during the previous 2 weeks. Responses to each of the 32 questions are on a 7-point scale (7=no impairment to 1=severe impairment). The overall AQLQ +12 score is the mean of all 32 responses. Overall scores range from 1=severe impairment to 7=no impairment. | mITT Population | Posted | Least Squares Mean | 95% Confidence Interval | Scores on a scale | Week 24 |
|
Serious Adverse events were collected from the time subject signed Informed Consent to the time of the final follow-up telephone call up to approximately 30 weeks. Adverse Events were collected from the time subject was randomized up to approximately 26 weeks.
The safety analysis set was defined as data from all subjects who were randomized to treatment and received any amount of the study treatment
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | GP MDI 28.8 μg | Glycopyrronium Metered Dose Inhalation 28.8 μg | 0 | 235 | 9 | 235 | 33 | 235 |
| EG001 | GP MDI 14.4 μg | Glycopyrronium Metered Dose Inhalation 14.4 μg | 0 | 240 | 7 | 240 | 35 | 240 |
| EG002 | GP MDI 7.2 μg | Glycopyrronium Metered Dose Inhalation 7.2μg | 0 | 240 | 6 | 240 | 33 | 240 |
| EG003 | Placebo MDI | Placebo Metered Dose Inhalation | 0 | 237 | 7 | 237 | 29 | 237 |
| EG004 | Spiriva Respimat 2.5 μg | Spiriva Respimat 2.5 μg | 0 | 119 | 2 | 119 | 14 | 119 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Urinary tract infection | Infections and infestations | MedDRA | Systematic Assessment |
| |
| Influenza | Infections and infestations | MedDRA | Systematic Assessment |
| |
| Cellulitis | Infections and infestations | MedDRA | Systematic Assessment |
| |
| Pneumonia | Infections and infestations | MedDRA | Systematic Assessment |
| |
| Arthritis infective | Infections and infestations | MedDRA | Systematic Assessment |
| |
| Kindey infection | Infections and infestations | medDRA | Systematic Assessment |
| |
| Klebsiella bacteraemia | Infections and infestations | MedDRA | Systematic Assessment |
| |
| Metapneumovirus infection | Infections and infestations | MedDRA | Systematic Assessment |
| |
| Pneumonia viral | Infections and infestations | MedDRA | Systematic Assessment |
| |
| Sepsis | Infections and infestations | MedDRA | Systematic Assessment |
| |
| Asthma | Respiratory, thoracic and mediastinal disorders | MedDRA | Systematic Assessment |
| |
| Pulmonary embolism | Respiratory, thoracic and mediastinal disorders | MedDRA | Systematic Assessment |
| |
| Respiratory failure | Respiratory, thoracic and mediastinal disorders | MedDRA | Systematic Assessment |
| |
| Concussion | Injury, poisoning and procedural complications | MedDRA | Systematic Assessment |
| |
| Cerbrovascular accident | Nervous system disorders | MedDRA | Systematic Assessment |
| |
| Adverse drug reaction | General disorders | MedDRA | Systematic Assessment |
| |
| Non cardiac chest pain | General disorders | MedDRA | Systematic Assessment |
| |
| Dehydration | Metabolism and nutrition disorders | MedDRA | Systematic Assessment |
| |
| Acute kidney injury | Renal and urinary disorders | MedDRA | Systematic Assessment |
| |
| Adnexal torsion | Reproductive system and breast disorders | MedDRA | Systematic Assessment |
| |
| Cholecystitis | Hepatobiliary disorders | MedDRA | Systematic Assessment |
| |
| Miscarriage of partner | Social circumstances | MedDRA | Systematic Assessment |
| |
| Abdominal pain | Gastrointestinal disorders | MedDRA | Systematic Assessment |
| |
| Acute respiratory failure | Respiratory, thoracic and mediastinal disorders | MedDRA | Systematic Assessment |
| |
| Nephrolithiasis | Renal and urinary disorders | MedDRA | Systematic Assessment |
| |
| Post traumatic pain | Injury, poisoning and procedural complications | MedDRA | Systematic Assessment |
| |
| Intervertebral disc protrusion | Musculoskeletal and connective tissue disorders | MEdDRA | Systematic Assessment |
| |
| Suicidal ideation | Psychiatric disorders | MedDRA | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Upper respiratory tract infection | Infections and infestations | MedDRA | Systematic Assessment |
| |
| Nasopharyngitis | Infections and infestations | MedDRA | Systematic Assessment |
| |
| Sinusitis | Infections and infestations | MedDRA | Systematic Assessment |
|
Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent it's opinions, or the opinions of the publication committee, if these differ with the proposed publication.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Pearl Therapeutics, Inc. | Pearl Therapeutics, Inc. | 1-877-240-9479 | information.center@astrazeneca.com |
| Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Aug 12, 2019 | May 22, 2020 | SAP_001.pdf |
Not provided
| ID | Term |
|---|---|
| D001249 | Asthma |
| ID | Term |
|---|---|
| D001982 | Bronchial Diseases |
| D012140 | Respiratory Tract Diseases |
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012130 | Respiratory Hypersensitivity |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |
Not provided
Not provided
| Male |
|
| Not Hispanic or Latino |
|
| Unknown or Not Reported |
|
| Asian |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
| Counts |
|---|
| Participants |
|
|
Spiriva Respimat 2.5 μg |
|
|
| OG003 | Placebo MDI | Placebo Metered Dose Inhalation |
| OG004 | Spiriva Respimat 2.5 μg | Spiriva Respimat 2.5 μg |
|
|
| OG004 |
| Spiriva Respimat 2.5 μg |
Spiriva Respimat 2.5 μg |
|
|
Glycopyrronium Metered Dose Inhalation 7.2μg
| OG003 | Placebo MDI | Placebo Metered Dose Inhalation |
| OG004 | Spiriva Respimat 2.5 μg | Spiriva Respimat 2.5 μg |
|
|